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Background: Cholecystokinin octapeptide (CCK-8), the most potent endogenous anti-opioid peptide, has been
shown to regulate the processes of morphine dependence. In our previous study, we found that exogenous CCK-8
attenuated naloxone induced withdrawal symptoms. To investigate the precise effect of exogenous CCK-8 and the
role of cholecystokinin (CCK) 1 and/or 2 receptors in morphine dependence, a SH-SY5Y cell model was employed,
in which the μ-opioid receptor, CCK1/2 receptors, and endogenous CCK are co-expressed.
Results: Forty-eight hours after treating SH-SY5Y cells with morphine (10 μM), naloxone (10 μM) induced a cAMP
overshoot, indicating that cellular morphine dependence had been induced. The CCK receptor and endogenous
CCK were up-regulated after chronic morphine exposure. The CCK2 receptor antagonist (LY-288,513) at 1–10 μM
inhibited the naloxone-precipitated cAMP overshoot, but the CCK1 receptor antagonist (L-364,718) did not.
Interestingly, CCK-8 (0.1-1 μM), a strong CCK receptor agonist, dose-dependently inhibited the naloxone-
precipitated cAMP overshoot in SH-SY5Y cells when co-pretreated with morphine. The L-364,718 significantly
blocked the inhibitory effect of exogenous CCK-8 on the cAMP overshoot at 1–10 μM, while the LY-288,513 did
not. Therefore, the CCK2 receptor appears to be necessary for low concentrations of endogenous CCK to potentiate
morphine dependence in SH-SY5Y cells. An additional inhibitory effect of CCK-8 at higher concentrations appears
to involve the CCK1 receptor.
Conclusions: This study reveals the difference between exogenous CCK-8 and endogenous CCK effects on the
development of morphine dependence, and provides the first evidence for the participation of the CCK1 receptor
in the inhibitory effects of exogenous CCK-8 on morphine dependence.
Keywords: Cholecystokinin octapeptide, CCK1 receptor, CCK2 receptor, Morphine, Cellular dependence,
cAMP overshootBackground
Opioids are not only potent analgesics but are also drugs
of abuse, which greatly limits their clinical use. Chronic
use of opioids results in the development of tolerance
and dependence. Recent studies suggest that non-opioid
systems could be important targets for the treatment of
opioid dependence [1,2]. Antagonism of opioid effects by
endogenous anti-opioid peptides is common [3]. Chole-
cystokinin (CCK) was initially identified as a gastroin-
testinal hormone, and was subsequently found in the* Correspondence: chunlingma@126.com
1Department of Forensic Medicine, Hebei Medical University, Hebei Key
Laboratory of Forensic Medicine, Shijiazhuang 050017, PR China
Full list of author information is available at the end of the article
© 2012 Wen et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcentral and peripheral nervous systems. It occurs as vari-
ous sized peptides, including 4, 8, 33, 39 and 58 amino
acid forms [4]. Cholecystokinin octapeptide (CCK-8) is
the most potent endogenous anti-opioid peptide [5]. For
example, morphine treatments enhance the overflow of
CCK, whereas CCK-8 and its analogues attenuate the an-
algesic effects of morphine [6-8]. Furthermore, studies
have demonstrated that the CCK system modulates a
variety of physiological processes, and that CCK-8 inter-
acts with the GABAergic and dopaminergic systems.
Thus, CCK-8 plays a significant role in a wide range
of central actions including memory and drug reward
[9-12]. Overlap in the distributions of CCK and opioid
receptors may be observed in some anatomical regionsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The SH-SY5Y cells were pretreated with morphine
(10 μM) exposure for 48 h, precipitated with naloxone (10 μM)
for 15 min, and then the levels of cAMP were measured. The
data are from the analysis of the ratio of the levels of cAMP relative
to the control (Sal+Sal), and are presented as the mean ± S.D. of
three separate experiments. ##P < 0.01, compared with the Sal + Sal
group; **P < 0.01, compared with the Mor + Sal group.
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ence [13]. These findings indicate that the CCK system
is related to the modulation of morphine tolerance
and dependence.
The administration of CCK receptor antagonists can
prevent or reverse tolerance to systemic exogenous
opioids or electroacupuncture-induced analgesia, as well
as suppress morphine withdrawal syndromes [14-16].
Interestingly, CCK receptor activation can reverse mor-
phine tolerance [17]. We previously found that chronic
pretreatment with exogenous CCK-8 significantly inhib-
ited naloxone-precipitated withdrawal symptoms, which
is the same effect as CCK-receptor antagonists [18,19].
These phenomena suggest that the effects of exogenous
CCK-8 are distinct from the role of endogenous CCK.
With regard to dosage, CCK-8 was able to prevent mor-
phine dependence at high, but not low, concentrations
[20]. However, no studies have reported a dose–response
curve of CCK-8 on morphine dependence. On the basis
of the pharmacological properties and specificities for
ligand binding, CCK receptors have been identified for
the CCK1 and CCK2 receptor subtypes [21]. The
expression pattern of these CCK receptors in mammals
appears to be tissue-specific [22]. Several studies have
revealed that two different CCK receptors (CCK1 and
CCK2) have opposing influences on behavioural and
hormonal actions [23,24]. Thus, CCK receptor subtypes
that mediate the inhibitory effects of exogenous CCK-8
on morphine dependence remain to be determined.
The biological basis of tolerance and dependence
induced by chronic exposure to opioids is thought to be
due to molecular, cellular, and neural network adapta-
tions. On the cellular level, opioid dependence is charac-
terised by a significant elevation of adenylyl cyclase (AC)
activity after drug withdrawal, which is a regulatory
phenomenon termed "AC supersensitivity" or "cAMP
overshoot" [25-27]. A cAMP overshoot represents an
opioid-dependent state in vitro and has been utilised
in the study of the effects of morphine dependence
[28]. This present study evaluates the effects of CCK-8
on the AMP overshoot based on a cellular model and
aims to clarify the exact effects of exogenous CCK-8.
In addition, the subtypes of CCK receptor that mediate
the function of CCK-8 on morphine dependence are
also investigated.
Results
In vitro model of morphine dependence
The SH-SY5Y cell line was used to examine the effects
of CCK-8 on cellular morphine dependence. It is well
established that up-regulation of the adenylate cyclase
effector system represents an in vitro opioid-dependent
state. Thus, withdrawal of opioids following chronic
treatment leads to a cAMP overshoot, which is alsoreferred to ‘cAMP super-sensitisation’, and is an in vitro
model of the abstinence state. In the present study, the
level of cAMP increased 1.57 (±0.08)-folds after mor-
phine treatment (10 μM; 48 h), and was elevated to 3.09
(±0.289)-folds after naloxone treatment, compared to
the non-treated cells (10 μM; 15 min). The analysis of
the data obtained from the cAMP tests with two-way
ANOVA revealed a significant morphine and naloxone
interaction (F1, 8 = 53.718, P< 0.001) on the cAMP level,
which indicated that the cAMP overshoot was signifi-
cantly induced by chronic morphine exposure following
naloxone precipitation (Figure 1).
The effect of chronic morphine exposure on the
endogenous CCK system
The expression of the opioid and CCK system in
SH-SY5Y cells was initially confirmed. Our results
revealed that the μ-opioid, CCK1 and CCK2 receptors
were co-expressed in SH-SY5Y cells, and that SH-SY5Y
cells contained endogenous CCK (Figure 2A). The effect
of chronic morphine exposure on the expression of
the endogenous CCK system in SH-SY5Y cells was mea-
sured. The expression of the CCK1/CCK2 receptor and
endogenous CCK mRNA were up-regulated 2.51(± 0.56)-,
6.10(± 0.91)- and 4.87(± 1.08)-fold (P=0.004, P< 0.001
and P< 0.001, respectively) after 10 μM morphine treat-
ment for 48 h (Figure 2B).
The effect of CCK receptor antagonists on naloxone-
precipitated cAMP overshoot in SH-SY5Y cells after
chronic morphine exposure
CCK-8 is the most potent endogenous anti-opioid pep-
tide and endogenous CCK expression is up-regulated
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Figure 2 A: MOR (μ-opioid receptor), CCK1R (CCK1 receptor), CCK2R (CCK2 receptor) and CCK mRNA are co-expressed in SH-SY5Y cells.
The PCR products were separated by 2% agarose gel electrophoresisi and imaged. Lane 1: MOR; Lane 2: CCK1R; Lane 3: CCK2R; Lane 4: CCK.
B: The effects of chronic morphine exposure (10 μM) for 48 h on CCK1R, CCK2R and endogenous CCK expression. The data are obtained from the
analysis of the fold of relative expression level compared to the saline control group, and expressed as the mean ± S.D. of three independent
experiments. **P<0.01, ***P<0.001 compared with the control by t-test.
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a CCK1 receptor antagonist, and LY-288,513, a CCK2
receptor antagonist (0.01-10 μM), were utilised to exam-
ine endogenous CCK regulation of the development of
morphine dependence in SH-SY5Y cells. Baseline experi-
ments were first conducted in the absence of the opioid.
Pretreatment with L-364,718 (F4, 10 = 0.593, P= 0.676)
or LY-288,513 (F4, 10 = 0.246, P= 0.905) alone did not
affect cellular basal cAMP levels (Figure 3A). Co-
pretreatment of LY-288,513 (1 and 10 μM) with mor-
phine (10 μM) for 48 h significantly inhibited cAMP
overshoot following naloxone (10 μM, 15 min) preci-
pitation (F4, 10 = 22.185, P< 0.001, Figure 3B), however,
L-364,718 exhibited no effect (F4,10 = 0.119, P= 0.972,
Figure 3B). Consistent with a previous study in vivo,
these findings suggest that endogenous CCKs have a
notable effect on morphine dependence in vitro via the
CCK2 receptor.The effect of exogenous CCK-8 on naloxone-precipitated
cAMP overshoot in SH-SY5Y cells after chronic morphine
exposure
Exogenous CCK-8 (0.1-1 μM), a CCK receptor agonist,
inhibited the naloxone (10 μM) precipitated cAMP over-
shoot when co-pretreated with morphine (10 μM; 48 h)
(F4, 10 = 8.914, P= 0.002, Figure 4B) in a dose-dependent
manner, indicating that exogenous CCK-8 has an identi-
cal regulatory effect on cellular morphine dependence as
the antagonist. A significant inhibitory effect was
observed at a concentration of 0.1 μM (P= 0.028) and
1 μM (P= 0.011), but not at 0.001 μM or 0.1 μM
(P= 0.722, P= 0.967), compared with the morphine pre-
treated control cells. Baseline experiments were con-
ducted in the absence of the opioid. Treatment with
CCK-8 at concentrations from 0.001 to 1 μM for 48 h
exhibited no effect on basal cAMP levels (F4, 10 = 0.132,
P= 0.967, Figure 4A). Moreover, exogenous CCK-8 did
A:   
B:   
Figure 3 The effect of L-364,718 or LY-288,513 on naloxone
precipitated cAMP overshoot in saline (A) or morphine (B)
pretreated SH-SY5Y cells. The SH-SY5Y cells were first co-
pretreated with L-364,718 or LY-288,513 (0-10 μM) and saline for 48
h to evaluate the effect of CCK receptor antagonists on the baseline
cAMP level, and then incubated with L-364,718 or LY-288,513 plus
morphine (10 μM) to investigate the influence of CCK receptor
antagonists on the naloxone (10 μM, 15 min) precipitated cAMP
overshoot. The control groups were considered as no CCK receptor
antagonist-treated cells (0 μM L-364,718/LY-288,513) in each
independent experiment. The results of the cAMP levels are
represented as the percentage of cAMP content relative to the
control group. The data are presented as the mean ± S.D. of three
separate experiments, performed in duplicate. **P < 0.01, ***P <
0.01, compared with the control by one-way ANOVA followed by
Dunnett’s t-test.
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10 = 2.685, P= 0.094, Figure 4C), indicating that a non-
specific inhibitory mechanism on cAMP shoot induced
by CCK-8 could be ruled out.
Blockade of the CCK1 receptor attenuates the effect of
exogenous CCK-8 on naloxone-precipitated cAMP
overshoot after chronic morphine exposure
As described above, CCK-8 (0.1-1 μM) inhibited nalox-
one precipitated cAMP overshoot when co-pretreated
with morphine in a dose-dependent manner. We then
blocked CCK1 and CCK2 receptors using L-364,718 andLY-288,513, respectively, to determine the role of
CCK receptor subtypes in exogenous CCK-8 regulating
morphine dependence. The cells were pre-treated with
L-364,718 (1 and 10 μM) or LY-288,513 (1 and 10 μM),
15 min before co-treatment of morphine (10 μM) and
CCK-8 (1 μM). Next, the cAMP overshoot was subse-
quently induced by adding 10 μM naloxone. The inhibi-
tory effect of CCK-8 on the naloxone precipitated cAMP
overshoot was significantly reduced at both 1 μM
(P= 0.003) and 10 μM (P< 0.001) L-364,718 pre-treated
cells (Figure 5). However, no change was observed in
1 μM (P= 0.373) and 10 μM (P= 0.069) LY-288,513 pre-
treated cells, indicating that the CCK1 receptor
mediated the effect of exogenous CCK-8 on cellular
morphine dependence. Due to the inhibitory function of
LY-288,513 and CCK-8 on the cAMP overshoot (Figure 3
and Figure 4), a cumulative effect of LY-288,513 and ex-
ogenous CCK-8 was not observed.
Discussion
In this present study, we describe a distinct effect of
exogenous CCK-8 on the development of morphine
dependence in vitro. Moreover, we provide the first piece
of evidence that a CCK1 receptor antagonist can reverse
the inhibitory effects of exogenous CCK-8 on morphine
dependence. We also find that endogenous CCK exerts a
potential facilitative effect via the CCK2 receptor. This
suggests opposing roles of CCK1 and CCK2 receptors in
the development of morphine dependence.
First, a suitable cell model was selected for this study.
The SH-SY5Y cell line is derived from a human neuro-
blastoma cell line, SK-N-SH, by three rounds of subclon-
ing. The SH-SY5Y cells are dopamine beta hydroxylase
active, acetylcholinergic, glutamatergic and adenosinergic,
and express abundant and functional μ- and δ-opioid
receptors. SH-SY5Y cells have been extensively used for
studies of opioid receptor regulation and intracellular sig-
naling. Moreover, co-expression of the opioid and CCK
systems in SH-SY5Y cells was confirmed, and CCK is
endogenously expressed in SH-SY5Y cells. This system is
useful for the study of the potential regulatory effects of
exogenous CCK-8 on morphine dependence.
The interaction between CCK and opioids was first
reported by Itoh et al. They showed that pre-treatment
with CCK suppressed anti-nociception induced by β-
endorphin [29]. A subsequent in vivo microdialysis study
found that the extracellular levels of CCK significantly
increased after morphine administration, thus acting as
a negative feedback modulator and a potent anti-opioid
peptide [6,7,30]. Studies have confirmed that endogen-
ous CCK potentiates, and the CCK antagonist attenuates
the tolerance and dependence of opioids [31,32]. The
presence of opioid receptors in CCK-containing neurons
suggest a potential direct influence of opioids on CCK
A:   
B:   C:   
Figure 4 The effects of CCK-8 on saline (A) or morphine (B) pretreated, naloxone precipitated cAMP overshoot and, on forskolin
stimulated cAMP accumulation (C) in SH-SY5Y cells. The SH-SY5Y cells were co-pretreated with CCK-8 (0.001-10 μM) and saline or 10 μM
morphine for 48 h to observe the effect of exogenous CCK-8 on the baseline cAMP levels and morphine withdrawal-induced cAMP overshoot,
respectively. The cells were then co-pretreated with CCK-8 (0.001-10 μM) and forskolin (10 μM) to rule out non-specific inhibition of CCK-8 on
the cAMP overshoot. The control groups were as the cells that received no CCK-8 (0 μM CCK-8) treatment in each independent experiment.
The results of the cAMP levels are represented as the percentage of cAMP content relative to the control group. The data are presented as the
mean ± S.D. of three separate experiments, performed in duplicate. *P < 0.05, compared with the control by one-way ANOVA followed by
Dunnett’s t-test.
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an affinity of CCK for opioid receptors, indicating that
CCK does not behave as a classical receptor antagonist
via binding to opioid receptors [34]. Han et al. found
that the binding of CCK-8 to the CCK receptor reduces
the binding affinity of μ-opioid receptor ligands, imply-
ing that receptor–receptor interaction between CCK
and opioid systems may occur in an indirect manner
[35]. The molecular cloning of CCK receptor subtypes,
one from the pancreas (type-1) and another from human
brain (type-2), has confirmed the pharmacological classi-
fication of CCK receptors. The CCK2 receptor is pre-
dominantly localised in the CNS, and mainly mediates
anxiety, panic attacks, pain and drug dependence [36-
38]. The CCK1 receptor is present in discrete regions
of the brain and has a low affinity for central CCK
[39], and its function is poorly understood with only a
few reports investigating the central role in food intake
regulation [40]. The use of highly selective receptor
antagonists and antisense approaches has shown, at least
in the rodent, that CCK2 receptors mediate the anti-
opioid function of CCK [41-43]. The present study shows
that co-pretreatment with LY-288,513 and morphinesignificantly inhibited the naloxone-precipitated cAMP
overshoot in SH-SY5Y cells, but that co-pretreatment
with L-364,718 displayed no effect. We verified that
endogenous CCK played an anti-opioid role and poten-
tiated the development of morphine dependence via the
CCK2 receptor.
Together with our previous results, we found that
exogenous CCK-8 pretreatment significantly inhibited
morphine dependence in vitro and in vivo [44]. These
results show that the treatments of the CCK receptor
agonist and antagonist demonstrated the same effect on
morphine dependence. Moreover, CCK-8 treatment
did not affect basal or forskolin-stimulated cAMP levels,
suggesting that the effect of exogenous CCK-8 was not
simply a direct action on cAMP. Several studies have
reported that small doses of CCK inhibit the anti-
nociceptive action of opioids, whereas large doses of
CCK induce analgesia [45]. We previously revealed that
CCK-8 suppressed the binding affinity of the μ-opioid
receptor in SH-SY5Y cells at concentrations of 1 nM,
while it increased the expression of the endogenous opi-
oid peptide from 0.1 to 1 μM [46]. The dose–response
curve of CCK-8 was inversely U-shaped, and CCK-8
Figure 5 The CCK1 receptor antagonist blocked the inhibitory
effects of exogenous CCK-8 on naloxone precipitated cAMP
overshoot after chronic morphine exposure. The SH-SY5Y cells
were co-pretreated with L-364,718(1 and 10 μM) or LY-288,513(1 and
10 μM) and CCK-8 (1 μM) plus morphine (10 μM) for 48 h. After the
removal of the drugs, naloxone (10 μM, 15 min) was added for the
induction of the cAMP overshoot. The control group was the no
CCK-8 and CCK receptor antagonist treated cells (Sal + Sal). The
results of the cAMP level are represented as the percentage of cAMP
content relative to the control group. The data are the mean ± S.D.
of three separate experiments, performed in duplicate. ##P < 0.01,
compared with the Sal + Sal group by t-test; **P < 0.01, ***P <
0.001 as compared with the Sal + CCK-8 group by one-way ANOVA
followed by Dunnett’s t-test.
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found that only high concentrations of CCK-8 were able
to attenuate the cAMP overshoot in a dose-dependent
manner. Thus, observations of exogenous CCK-8 may
represent pharmacological effects, rather than physio-
logical effects of endogenous CCK.
A previous study indicated that the CCK1 receptor
was ineffective in the development of morphine depend-
ence [42]. Nevertheless, we found that a high dose of
exogenous CCK-8 markedly attenuated the naloxone
precipitated cAMP overshoot via the CCK1 receptor.
We concluded that the CCK1 and CCK2 receptors play
unique and distinct roles in physiology and pathophysi-
ology. Moreover, data showing that CCK1 receptors
mediate mnemonic effects, and that CCK2 receptors
mediate amnestic effects, have been reported [48]. Fur-
thermore, CCK evokes [Ca2+]i signaling by the influx
of extracellular calcium, likely through L-type calcium
channels, and an antagonist for the CCK1 receptor
blocked [Ca2+]i response to CCK-8 [49,50]. CCK pro-
duces direct neuronal depolarisation via CCK1 receptors
and inhibits GABAergic synaptic transmission [51], while
CCK2 receptor activation augments long-term potenti-
ation in hippocampal slices [52]. CCK-8, the predomin-
ant central form of CCK, has a high affinity for theCCK2 receptor, but a low affinity for the CCK1 receptor.
The CCK1 receptor is activated only in the presence
of high CCK-8 levels, and exerts a different effect from
the CCK2 receptor on morphine dependence. Due to the
inhibitory function of LY-288,513 and CCK-8 on cAMP
overshoot, the cumulative effect of LY-288,513 and
exogenous CCK-8 on cAMP overshoot was not observed.
The role of CCK2 receptor in the process of exogenous
CCK-8 regulation on morphine dependence can not be
ruled out.
Conclusions
In conclusion, we identified a difference between the
role of the CCK1 and CCK2 receptor on the develop-
ment of morphine dependence and an inhibitory effect
of high-doses of exogenous CCK-8 on cellular morphine
dependence. In addition, this study provides the first evi-
dence for the participation of the CCK1 receptor in the




Morphine hydrochloride was purchased from Shenyang
First Pharmaceutical Factory (Liaoning, China). CCK-8,
IBMX, naloxone and forskolin were purchased from
Sigma (Sigma, St. Louis, MO, USA). Retinoic acid (RA)
was purchased from Alfa Aesar (Alfa Aesar, Heysham,
UK). The CCK1 receptor antagonist, L-364,718, and
CCK2 receptor antagonist, LY-288,513, were purchased
from Tocris Bioscience (Tocris Cookson, Northpoint,
UK). DMEM/F12 medium was purchased from Invitro-
gen Corporation (Gibco™, Grand Island, NY, USA). Fetal
bovine serum was purchased from PAA Laboratories
(PAA, Strasse, Pasching, Austria). LANCE™ cAMP kits
were purchased from PerkinElmer (PerkinElmer, MA,
USA). CCK-8 was suspended in vehicle consisting of 1%
ammonia saline solution at 1 mg/ml, and the CCK recep-
tor antagonists were suspended in DMSO at 1 mg/ml.
Cell culture
Human SH-SY5Y neuroblastoma cells were obtained
from Shanghai Bioleaf Biotec (Shanghai, China). The
cells were seeded at 1 × 106 cell/25 cm2 in tissue culture
flasks and grown in DMEM/F12 medium supplemented
with 10% fetal bovine serum, 100 U/ml penicillin and
100 U/ml streptomycin for 24 hours. The cells were then
morphologically differentiated into neuron-like cells by
treatment with10 mM RA. Similar with previous studies
[53], the RA-containing medium was replaced every
2 days. The cultured SH-SY5Y cells were then used for
experiments 6 days after the initiation of differentiation.
All of the cultures were maintained at 37 °C in a humidi-
fied atmosphere consisting of 95% air and 5% CO2.






β-actin 5’-GGGACCT GACTGACTACCTC-3’ 5’-ACTCGTCATACTCCTGCTTG-3’
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The cells were harvested and the total RNA was
extracted with TriZol Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. The
RNA concentrations were determined using a Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA), and the complementary DNA
(cDNA) was synthesised from the total RNA (500 ng)
using the PrimeScript™ RT regent Kit (Takara Biotech-
nology, Dalian, China) following the instructions pro-
vided by the manufacturer. Subsequently, the cDNA was
subjected to real-time PCR using the Power SYBR Green
PCR Master Mix (Takara Biotechnology, Dalian, China).
Each real-time PCR reaction consisted of 2 μl of diluted
RT product, 10 μl SYBR Green PCR Master Mix and
250-nm specific primer pairs (Table 1) in a total volume
of 20 μl. The reactions were performed on a 7500 real-
time PCR System (Applied Biosystems) for 40 cycles
(95 °C for 5 s, 60 °C for 35 s) after an initial 30 s incuba-
tion at 95 °C. The PCR products were separated by 2%
agarose gel electrophoresis, illuminated with UV light
and imaged to assess the amplification. The fold change
in the mRNA levels of each gene was calculated using
the ΔΔCt method, with the house keeping gene, β-actin,
as an internal control.
cAMP accumulation assays
The differentiated SH-SY5Y cells that had been treated
with morphine and/or CCK-8 for 48 h were assayed
for cAMP accumulation using a LANCE™ cAMP kit
(PerkinElmer). The cells were harvested with a Versene
dissociation solution followed by washing with HBSS
buffer. The cells were then resuspended at a concentra-
tion of 2 × 106 cells/ml in stimulation buffer (HBSS 1×,
containing 5 mM HEPES, 0.1% BSA, 0.05 mM IBMX).
The Alexa pluorW647 labeled antibodies were added to
the final cell suspension, and then naloxone was added
to the cell suspension to precipitate the cAMP over-
shoot. After incubation at 37 °C for 15 min, the Detec-
tion Mix was added to the mixture. The sample was
further incubated for 1 h, and was read on a TECAN
instrument (Infinitie F200, Tecan, Grodig, Austria) to
measure the LANCE signal. Simultaneous to the meas-
urement of the cell-based cAMP level, the cAMP stand-
ard curve was assayed according to the manufacturer’sinstructions. The LANCE signal obtained at 665 nM
can be directly used to analyse the cAMP levels. The
signal at 615 nM is useful to identify dispensing or
quenching problems.
Statistical analysis
The data are presented as the mean ± standard deviation
(S.D.) All of the experiments were performed at least
three times, each with a different culture. The statistical
analyses (SPSS, v. 13.0, Chicago, USA) were performed
with two-way ANOVA to evaluate the interaction
between morphine and naloxone on the cAMP over-
shoot to estabish the cellular model of morphine
dependence, and then with t-test and one-way ANOVA
followed by Dunnett’s t-test for subsequent experiments.
A P-value <0.05 was considered statistically significant.
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